Haiying Zhou

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 3

Top Topics

Locally Advanced

Chemotherapy Induced

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Christopher T Chen, Vishesh Khanna, Shivaani Kummar, Raghad M Abdul-Karim, David Sommerhalder, Anthony W Tolcher, Naoto Tada Ueno, S Lindsey Davis, Douglas W Orr, Erika Paige Hamilton, Manish R Patel, Alexander I Spira, Shekeab Jauhari, Vaia Florou, Maureen Duff, Rongda Xu, Jian Wang, Shravani R Barkund, Haiying Zhou, Aleksandr Pankov, Wayne Kong, Nadine S Jahchan, Erica L Jackson, Jessica D Sun, Melissa R Junttila, Pratik S Multani, Anneleen Daemen, Edna Chow-Maneval, Pamela N Munster
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. Cancer research communications (2024)
Anthony Cao, Jiaqing Yi, Xinyan Tang, Christopher W Szeto, Renyi Wu, Bing Wan, Xu Fang, Shou Li, Lei Wang, Lina Wang, Jing Li, Qiuping Ye, Tom Huang, Karl Hsu, Omar Kabbarah, Haiying Zhou
CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy. Cancer research communications 2 (11) (2022)
Anthony Cao, Jiaqing Yi, Xinyan Tang, Christopher W Szeto, Renyi Wu, Bing Wan, Xu Fang, Shou Li, Lei Wang, Lina Wang, Jing Li, Qiuping Ye, Tom Huang, Karl Hsu, Omar Kabbarah, Haiying Zhou
CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy. Cancer research communications 2 (11) (2022)